Yahui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yahui Liu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Kai Liu
Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
11 shared publicationsWei Zhang
Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
11 shared publications- Songyang Liu
Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
8 shared publications Bai Ji
Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
7 shared publicationsYingchao Wang
Department of Hepatopancreatobiliary Surgery, The First Hospital, Jilin university, Changchun, Jilin, P.R. China
6 shared publicationsSongyang Liu
Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
4 shared publications
Latest Publications
- RetractionOpen Access
- 11 July 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (3) , 1
[Retracted] MicroRNA‑744 inhibits migration and invasion of hepatocellular carcinoma cells by targeting SOX12
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the cell migration assay data shown in Fig. 3B were strikingly similar to data that had appeared in different form in another article by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 40: 3585‑3592, 2018; DOI: 10.3892/or.2018.6774]
- 11 July 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (3) , 1
RetractionOpen Access[Retracted] MicroRNA‑744 inhibits migration and invasion of hepatocellular carcinoma cells by targeting SOX12
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the cell migration assay data shown in Fig. 3B were strikingly similar to data that had appeared in different form in another article by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 40: 3585‑3592, 2018; DOI: 10.3892/or.2018.6774]
- RetractionOpen Access
- 30 November 2021
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (2) , 1
[Retracted] miR‑494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN
Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the western blotting data in Figs. 3 and 6 were strikingly similar to data appearing in different form in other articles by different authors at different research institutes. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 34: 1003‑1010, 2015; DOI: 10.3892/or.2015.4030]
- 30 November 2021
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (2) , 1
RetractionOpen Access[Retracted] miR‑494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN
Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the western blotting data in Figs. 3 and 6 were strikingly similar to data appearing in different form in other articles by different authors at different research institutes. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 34: 1003‑1010, 2015; DOI: 10.3892/or.2015.4030]
- RetractionOpen Access
- 26 November 2021
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (2) , 1-10
[Retracted] Synergistic effects of co‑expression plasmid‑based ADAM10‑specific siRNA and GRIM‑19 on hepatocellular carcinoma in vitro and in vivo
Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that various data featured in several of the figures were strikingly similar to data appearing in different form in other articles by different authors. An independent enquiry was launched by the Editorial Office, which revealed that cell migration assay data featured in Fig. 5A and C of the above article had been included in another article written by different authors submitted for publication some 12 months previously. Owing to the fact that the contentious data in the above article were already under consideration for publication prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 32: 2501-2510, 2014; DOI: 10.3892/or.2014.3503].
- 26 November 2021
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (2) , 1-10
RetractionOpen Access[Retracted] Synergistic effects of co‑expression plasmid‑based ADAM10‑specific siRNA and GRIM‑19 on hepatocellular carcinoma in vitro and in vivo
Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that various data featured in several of the figures were strikingly similar to data appearing in different form in other articles by different authors. An independent enquiry was launched by the Editorial Office, which revealed that cell migration assay data featured in Fig. 5A and C of the above article had been included in another article written by different authors submitted for publication some 12 months previously. Owing to the fact that the contentious data in the above article were already under consideration for publication prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 32: 2501-2510, 2014; DOI: 10.3892/or.2014.3503].
- RetractionOpen Access
- 1 November 2021
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 59 (6) , 1
[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the flow cytometric data in Fig. 3A and western blotting data featured in Figs. 3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 45: 1537‑1546, 2014; DOI: 10.3892/ijo.2014.2577]
- 1 November 2021
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 59 (6) , 1
RetractionOpen Access[Retracted] miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the flow cytometric data in Fig. 3A and western blotting data featured in Figs. 3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 45: 1537‑1546, 2014; DOI: 10.3892/ijo.2014.2577]
- Retracted
- 8 October 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (6) , 3585-3592
MicroRNA‑744 inhibits migration and invasion of hepatocellular carcinoma cells by targeting SOX12
MicroRNA‑744 (miR‑744) reportedly plays an oncogenic or tumor‑suppressive role in different human malignancies. Although a previous study demonstrated that miR‑744 significantly inhibits hepatocellular carcinoma (HCC) proliferation in vitro, the role of miR‑744 in the migration and invasion of HCC cells remains largely unknown. The present study investigated the significance of miR‑744 in HCC tissues and cell lines and evaluated its role and underlying mechanism of action in HCC cells. miR‑744 expression was detected in HCC tissues and cell lines by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The effect of miR‑744 on cell proliferation, migration and invasion was determined using Cell Counting Kit‑8, wound‑healing and Matrigel invasion assays, respectively. Targeting gene of miR‑744 in HCC cells was determined by luciferase reporter assay, RT‑qPCR and western blotting. It was revealed that miR‑744 was poorly expressed in HCC tissues compared with adjacent normal tissues (P<0.05), and that decreased miR‑744 levels were significantly associated with the tumor node metastasis stage and lymph node metastasis. Additionally, restoration of miR‑744 in HCC cells significantly suppressed their proliferation, migration, and invasion. Furthermore, sex determining region Y‑box 12 (SOX12) was identified as a functional target of miR‑744 in HCC cells, and its expression was demonstrated to be upregulated in HCC tissues and inversely correlated with the expression of miR‑744. Notably, overexpression of SOX12 antagonized the suppressive effect of miR‑744 on HCC cell migration and invasion. These findings suggested that miR‑744 inhibited migration and invasion by targeting SOX12, and that it may represent a therapeutic target for the treatment of metastatic HCC.
- 8 October 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (6) , 3585-3592
RetractedMicroRNA‑744 inhibits migration and invasion of hepatocellular carcinoma cells by targeting SOX12
MicroRNA‑744 (miR‑744) reportedly plays an oncogenic or tumor‑suppressive role in different human malignancies. Although a previous study demonstrated that miR‑744 significantly inhibits hepatocellular carcinoma (HCC) proliferation in vitro, the role of miR‑744 in the migration and invasion of HCC cells remains largely unknown. The present study investigated the significance of miR‑744 in HCC tissues and cell lines and evaluated its role and underlying mechanism of action in HCC cells. miR‑744 expression was detected in HCC tissues and cell lines by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The effect of miR‑744 on cell proliferation, migration and invasion was determined using Cell Counting Kit‑8, wound‑healing and Matrigel invasion assays, respectively. Targeting gene of miR‑744 in HCC cells was determined by luciferase reporter assay, RT‑qPCR and western blotting. It was revealed that miR‑744 was poorly expressed in HCC tissues compared with adjacent normal tissues (P<0.05), and that decreased miR‑744 levels were significantly associated with the tumor node metastasis stage and lymph node metastasis. Additionally, restoration of miR‑744 in HCC cells significantly suppressed their proliferation, migration, and invasion. Furthermore, sex determining region Y‑box 12 (SOX12) was identified as a functional target of miR‑744 in HCC cells, and its expression was demonstrated to be upregulated in HCC tissues and inversely correlated with the expression of miR‑744. Notably, overexpression of SOX12 antagonized the suppressive effect of miR‑744 on HCC cell migration and invasion. These findings suggested that miR‑744 inhibited migration and invasion by targeting SOX12, and that it may represent a therapeutic target for the treatment of metastatic HCC.
- RetractedOpen Access
- 6 February 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (3) , 1857-1864
miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma
Expression of miR-365 has been reported to be downregulated in hepatocellular carcinoma (HCC). However, the biological function and underlying mechanism of miR-365 in HCC growth and metastasis remain unclear. The aim of the present study was to explore the role of miR-365 in HCC progression. We found that miR-365 expression was downregulated in HCC tissues and cell lines. Further results showed that low expression of miR-365 was significantly associated with tumor-node-metastasis (TNM) stage and lymph node metastasis. Functional assays revealed that overexpression of miR-365 significantly inhibited cell proliferation, colony formation, migration and invasion of HCC cells in vitro, and suppressed tumor growth in vivo. Mechanistic investigations demonstrated that ADAM10 (a disintegrin and metalloproteinase 10) is a target of miR-365 in HCC. In addition, knockdown of ADAM10 in HepG2 cells significantly inhibited cell proliferation, colony formation, migration and invasion, which mimicked the suppressive effects induced by miR-365 overexpression. Restoration of ADAM10 expression partially reversed the suppressive effects mediated by miR-365 overexpression. Taken together, these results indicate that miR-365 functions as a tumor-suppressor in HCC through targeting ADAM10, and may serve as a promising candidate for therapeutic applications in HCC treatment.
- 6 February 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (3) , 1857-1864
RetractedOpen AccessmiR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma
Expression of miR-365 has been reported to be downregulated in hepatocellular carcinoma (HCC). However, the biological function and underlying mechanism of miR-365 in HCC growth and metastasis remain unclear. The aim of the present study was to explore the role of miR-365 in HCC progression. We found that miR-365 expression was downregulated in HCC tissues and cell lines. Further results showed that low expression of miR-365 was significantly associated with tumor-node-metastasis (TNM) stage and lymph node metastasis. Functional assays revealed that overexpression of miR-365 significantly inhibited cell proliferation, colony formation, migration and invasion of HCC cells in vitro, and suppressed tumor growth in vivo. Mechanistic investigations demonstrated that ADAM10 (a disintegrin and metalloproteinase 10) is a target of miR-365 in HCC. In addition, knockdown of ADAM10 in HepG2 cells significantly inhibited cell proliferation, colony formation, migration and invasion, which mimicked the suppressive effects induced by miR-365 overexpression. Restoration of ADAM10 expression partially reversed the suppressive effects mediated by miR-365 overexpression. Taken together, these results indicate that miR-365 functions as a tumor-suppressor in HCC through targeting ADAM10, and may serve as a promising candidate for therapeutic applications in HCC treatment.
- 15 June 2016
- Vol. 8 (6) , 2609-19
miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma.
MicroRNAs (miRNAs) are a class of small, non-coding RNAs that play a crucial role in tumor procession. It has been demonstrated that miR-449a expression was downregulated and served as tumor suppressor in many types of tumor. However, the biological function and molecular mechanism of miR-449a in hepatocellular carcinoma (HCC) still remains largely unknown. Therefore, the aims of this study were to investigate biological role and molecular mechanism of miR-449a in HCC by a serial of molecular experiments. Here, we demonstrated that miR-449a expression was downregulated in HCC tissues and cell lines compared with the adjacent nontumor tissues and normal hepatic cell line. Ectopic expression of miR-449a suppressed HCC cell proliferation, colony formation, migration and invasion. Moreover, A Disintegrin And Metalloproteinases 10 (ADAM10) was identified as a direct target gene of miR-449a in HCC cell. ADAM10 expression was upregulated in HCC tissues and cell lines, and was negatively correlated with the expression level of miR-449a in HCC tissues. Interesting, overexpression of ADAM10 attenuated the inhibition effect of miR-449a-mediated HCC cell proliferation, colony formation, migration and invasion. These results suggested that miR-449a might function as a tumor suppressor miRNA, at least in part, through regulating ADAM10 expression in HCC.
- 15 June 2016
- Vol. 8 (6) , 2609-19
miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma.
MicroRNAs (miRNAs) are a class of small, non-coding RNAs that play a crucial role in tumor procession. It has been demonstrated that miR-449a expression was downregulated and served as tumor suppressor in many types of tumor. However, the biological function and molecular mechanism of miR-449a in hepatocellular carcinoma (HCC) still remains largely unknown. Therefore, the aims of this study were to investigate biological role and molecular mechanism of miR-449a in HCC by a serial of molecular experiments. Here, we demonstrated that miR-449a expression was downregulated in HCC tissues and cell lines compared with the adjacent nontumor tissues and normal hepatic cell line. Ectopic expression of miR-449a suppressed HCC cell proliferation, colony formation, migration and invasion. Moreover, A Disintegrin And Metalloproteinases 10 (ADAM10) was identified as a direct target gene of miR-449a in HCC cell. ADAM10 expression was upregulated in HCC tissues and cell lines, and was negatively correlated with the expression level of miR-449a in HCC tissues. Interesting, overexpression of ADAM10 attenuated the inhibition effect of miR-449a-mediated HCC cell proliferation, colony formation, migration and invasion. These results suggested that miR-449a might function as a tumor suppressor miRNA, at least in part, through regulating ADAM10 expression in HCC.
- Retracted
- 9 July 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (12) , 9779-9788
MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma
MicroRNAs (miRNAs) are a class of small non-coding RNAs and have critical roles in tumorigenesis and metastasis. A growing body of evidence showed that microRNA-133a (miR-133a) was downregulated and played tumor suppressor roles in gastric, colorectal, bladder, and lung cancer. However, the role and underlying molecular mechanism of miR-133a in hepatocellular carcinoma (HCC) remain unclear. In this study, we analyzed the expression of miR-133a in HCC tissues and HCC cell lines. We find that miR-133a was downregulated in HCC tissues and cell lines and that miR-133a expression negatively correlated with tumor differentiation (P < 0.01), TNM stage (P < 0.01), and lymph node metastasis (P < 0.01). Then, functional studies demonstrate that restoration of miR-133a in HepG2 cells significantly suppressed proliferation, colony formation, migration, and invasion, induced cell cycle arrest at G0/G1 stage and cell apoptosis in vitro, and decreased tumor size and weight in a nude mouse HepG2 xenograft model. Using bioinformatics method and dual luciferase assays identified insulin-like growth factor 1 receptor (IGF-1R) as a direct target of miR-133a in HCC cells. Furthermore, overexpression of miR-133a inhibited activation AKT and ERK signal pathway, which contributed to suppression of HCC cell growth. These findings suggest that miR-133a may act as a tumor suppressor and inhibited survival of HCC cells by targeting IGF-1R.
- 9 July 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (12) , 9779-9788
RetractedMicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma
MicroRNAs (miRNAs) are a class of small non-coding RNAs and have critical roles in tumorigenesis and metastasis. A growing body of evidence showed that microRNA-133a (miR-133a) was downregulated and played tumor suppressor roles in gastric, colorectal, bladder, and lung cancer. However, the role and underlying molecular mechanism of miR-133a in hepatocellular carcinoma (HCC) remain unclear. In this study, we analyzed the expression of miR-133a in HCC tissues and HCC cell lines. We find that miR-133a was downregulated in HCC tissues and cell lines and that miR-133a expression negatively correlated with tumor differentiation (P < 0.01), TNM stage (P < 0.01), and lymph node metastasis (P < 0.01). Then, functional studies demonstrate that restoration of miR-133a in HepG2 cells significantly suppressed proliferation, colony formation, migration, and invasion, induced cell cycle arrest at G0/G1 stage and cell apoptosis in vitro, and decreased tumor size and weight in a nude mouse HepG2 xenograft model. Using bioinformatics method and dual luciferase assays identified insulin-like growth factor 1 receptor (IGF-1R) as a direct target of miR-133a in HCC cells. Furthermore, overexpression of miR-133a inhibited activation AKT and ERK signal pathway, which contributed to suppression of HCC cell growth. These findings suggest that miR-133a may act as a tumor suppressor and inhibited survival of HCC cells by targeting IGF-1R.
- Retracted
- 4 June 2015
- Published by Spandidos Publications in Oncology Reports
- Vol. 34 (2) , 1003-1010
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 4 June 2015
- Published by Spandidos Publications in Oncology Reports
- Vol. 34 (2) , 1003-1010
RetractedmiR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- Open Access
- 4 April 2015
- Published by Springer Nature in European Journal of Medical Research
- Vol. 20 (1) , 48
Hepatic endometriosis: a rare case and review of the literature
Hepatic endometriosis is one of the rarest disorders characterized by the presence of ectopic endometrium in the liver. To our knowledge, only 21 cases of hepatic endometrioma have been described in the medical literature. We report a case of a 36-year-old primiparous female with hepatic endometriosis forming a large cystic mass. The patient presented once with severe right quadrant pain as her only symptom and no history of endometriosis. Complete blood count and biochemical tests were normal. Abdominal ultrasonography and computed tomography scans suggested the presence of a 6.5 × 6.0 cm cystic mass in segment III of the liver. The mass was completely removed by local liver resection. The intraoperative frozen sections suggested a diagnosis of hepatic endometriosis. The diagnosis was confirmed through histological immunostaining without intrinsic abnormality. A preoperative diagnosis of hepatic endometriosis is made on the basis of considering the possibility in advance. Hepatic endometriosis should be considered in the differential diagnosis of a cystic liver mass despite conducting exhaustive investigations in the absence of characteristic clinical and radiological features. Histological examination is essential, and surgery remains the treatment of choice.
- 4 April 2015
- Published by Springer Nature in European Journal of Medical Research
- Vol. 20 (1) , 48
Open AccessHepatic endometriosis: a rare case and review of the literature
Hepatic endometriosis is one of the rarest disorders characterized by the presence of ectopic endometrium in the liver. To our knowledge, only 21 cases of hepatic endometrioma have been described in the medical literature. We report a case of a 36-year-old primiparous female with hepatic endometriosis forming a large cystic mass. The patient presented once with severe right quadrant pain as her only symptom and no history of endometriosis. Complete blood count and biochemical tests were normal. Abdominal ultrasonography and computed tomography scans suggested the presence of a 6.5 × 6.0 cm cystic mass in segment III of the liver. The mass was completely removed by local liver resection. The intraoperative frozen sections suggested a diagnosis of hepatic endometriosis. The diagnosis was confirmed through histological immunostaining without intrinsic abnormality. A preoperative diagnosis of hepatic endometriosis is made on the basis of considering the possibility in advance. Hepatic endometriosis should be considered in the differential diagnosis of a cystic liver mass despite conducting exhaustive investigations in the absence of characteristic clinical and radiological features. Histological examination is essential, and surgery remains the treatment of choice.